New combo therapy aims to shrink tough head and neck cancers
NCT ID NCT07062354
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 16 times
Summary
This study tests a combination of the targeted drug amivantamab plus two chemotherapy drugs (carboplatin and paclitaxel) in 50 adults with head and neck cancer that has come back or spread. Participants have already tried a PD-1 inhibitor. The goal is to see if the combination can shrink tumors and control the disease. The study is currently enrolling by invitation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD & NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Arizona Cancer Center
Tucson, Arizona, 85719, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.